GenAssist

Executive Summary

GenAssist is a preclinical-stage biotechnology company developing MyoMatrix™ (MyoSponge™), an acellular, implantable extracellular matrix scaffold designed to regenerate functional muscle tissue after volumetric muscle loss (VML). Unlike current treatments that lead to scar formation, MyoMatrix™ promotes true tissue regeneration by providing a structural and biochemical template for host cell infiltration and differentiation. Founded in 2019 and headquartered in San Francisco with R&D in St. Louis, the company addresses a significant unmet need in traumatic injury and reconstructive surgery. While still in preclinical development, GenAssist's approach leverages proven ECM biology and could offer a transformative solution for severe muscle wounds. The company has yet to disclose funding or valuation, but its technology holds promise for both military and civilian applications. Key near-term milestones include completing large animal efficacy studies and advancing toward an IND application.

Upcoming Catalysts (preview)

• Q3 2026Large Animal Study Results60% success
• Q4 2026Series A Financing50% success
• Q1 2027Pre-IND Meeting with FDA70% success